Prognia
Drug Database
🇪🇺EU · EMAAuthorisedATC: J07AH09

Bexsero(outer membrane vesicles from neisseria meningitidis group b (strain nz 98/254);recombinant Neisseria meningitidis group B fHbp fusion protein;recombinant Neisseria meningitidis group B NadA protein;recombinant Neisseria meningitidis group B NHBA fusion protein)

Meningitis, Meningococcal

Marketing Authorisation Holder: GSK Vaccines S.r.l.

EMA Authorisation: 13/01/2013

INN: meningococcal group B Vaccine (rDNA, component, adsorbed)

Indication

Active immunisation against invasive disease caused by Neisseria meningitidis serogroup-B strains.

Official EMA Resources

View on EMA (ema.europa.eu)

AI Drug & Interaction Analysis

Free account required

Ask Prognia AI about Bexsero — dosing recommendations, drug interactions, and current guideline evidence from ESC, EMA, NICE and more.

Ask about BexseroCreate Free Account

Medical disclaimer: This information is intended for qualified healthcare professionals. Always verify with the official EMA Summary of Product Characteristics (SmPC) before clinical use.